JP2017523974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523974A5 JP2017523974A5 JP2017505180A JP2017505180A JP2017523974A5 JP 2017523974 A5 JP2017523974 A5 JP 2017523974A5 JP 2017505180 A JP2017505180 A JP 2017505180A JP 2017505180 A JP2017505180 A JP 2017505180A JP 2017523974 A5 JP2017523974 A5 JP 2017523974A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- injection
- administered
- months
- methotrexate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462030778P | 2014-07-30 | 2014-07-30 | |
| US62/030,778 | 2014-07-30 | ||
| PCT/US2015/042951 WO2016019165A1 (en) | 2014-07-30 | 2015-07-30 | Methotrexate for proliferative vitreoretinopathy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020202357A Division JP2021059554A (ja) | 2014-07-30 | 2020-12-07 | 増殖性硝子体網膜症用メトトレキサート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523974A JP2017523974A (ja) | 2017-08-24 |
| JP2017523974A5 true JP2017523974A5 (https=) | 2022-04-27 |
| JP7097181B2 JP7097181B2 (ja) | 2022-07-07 |
Family
ID=55218325
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505180A Active JP7097181B2 (ja) | 2014-07-30 | 2015-07-30 | 増殖性硝子体網膜症用メトトレキサート |
| JP2020202357A Pending JP2021059554A (ja) | 2014-07-30 | 2020-12-07 | 増殖性硝子体網膜症用メトトレキサート |
| JP2023114963A Pending JP2023145527A (ja) | 2014-07-30 | 2023-07-13 | 増殖性硝子体網膜症用メトトレキサート |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020202357A Pending JP2021059554A (ja) | 2014-07-30 | 2020-12-07 | 増殖性硝子体網膜症用メトトレキサート |
| JP2023114963A Pending JP2023145527A (ja) | 2014-07-30 | 2023-07-13 | 増殖性硝子体網膜症用メトトレキサート |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US10098884B2 (https=) |
| EP (3) | EP3174540B9 (https=) |
| JP (3) | JP7097181B2 (https=) |
| CA (2) | CA2991921C (https=) |
| ES (2) | ES2969374T3 (https=) |
| WO (1) | WO2016019165A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2969374T3 (es) * | 2014-07-30 | 2024-05-17 | Massachusetts Eye & Ear Infirmary | Metotrexato para la vitreorretinopatía proliferativa |
| US20200179392A1 (en) * | 2016-08-05 | 2020-06-11 | Schepens Eye Research Institute | Idelalisib for Treating Proliferative Vitreoretinopathy and Abnormal Intraocular Neovascularization |
| US11739326B2 (en) | 2017-11-14 | 2023-08-29 | Massachusetts Eye And Ear Infirmary | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition |
| EP4028015A4 (en) * | 2019-09-13 | 2023-11-15 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations of methotrexate |
| CN115804665A (zh) * | 2022-12-13 | 2023-03-17 | 南昌大学附属眼科医院 | 一种tpvr动物模型的建立方法 |
| WO2024129979A1 (en) * | 2022-12-14 | 2024-06-20 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
| US11911385B1 (en) | 2022-12-14 | 2024-02-27 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020032734A1 (en) | 2000-07-26 | 2002-03-14 | Rhoads Geoffrey B. | Collateral data combined with user characteristics to select web site |
| AUPQ496500A0 (en) | 2000-01-06 | 2000-02-03 | University Of Sydney, The | Kit |
| US20040253243A1 (en) * | 2003-01-21 | 2004-12-16 | David Epstein | Aptamer therapeutics useful in ocular pharmacotherapy |
| US20050255144A1 (en) | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| US7807675B2 (en) * | 2004-04-02 | 2010-10-05 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid-methotrexate conjugate |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| EP1611879B1 (en) | 2004-07-02 | 2009-08-12 | Novagali Pharma SA | Use of emulsions for intra- and periocular injection |
| US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| KR101341359B1 (ko) * | 2004-10-01 | 2013-12-13 | 램스코르 인코포레이티드 | 편리하게 이식가능한 서방형 약물 조성물 |
| US8231892B2 (en) | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
| US20090081277A1 (en) * | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Pharmaceutical formulations and methods for treating ocular conditions |
| WO2010047803A2 (en) | 2008-10-22 | 2010-04-29 | Oncotx, L.L.C. | A method for the treatment of proliferative disorders of the eye |
| US9770414B2 (en) | 2010-05-13 | 2017-09-26 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
| US20140105956A1 (en) | 2012-10-11 | 2014-04-17 | Rupak BANERJEE | Biodegradable polymer based microimplant for ocular drug delivery |
| MX373894B (es) * | 2012-11-08 | 2020-07-09 | Clearside Biomedical Inc | Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos. |
| ES2969374T3 (es) * | 2014-07-30 | 2024-05-17 | Massachusetts Eye & Ear Infirmary | Metotrexato para la vitreorretinopatía proliferativa |
-
2015
- 2015-07-30 ES ES20191599T patent/ES2969374T3/es active Active
- 2015-07-30 WO PCT/US2015/042951 patent/WO2016019165A1/en not_active Ceased
- 2015-07-30 JP JP2017505180A patent/JP7097181B2/ja active Active
- 2015-07-30 CA CA2991921A patent/CA2991921C/en active Active
- 2015-07-30 EP EP15827946.3A patent/EP3174540B9/en active Active
- 2015-07-30 CA CA3200870A patent/CA3200870A1/en active Pending
- 2015-07-30 ES ES15827946T patent/ES2835499T3/es active Active
- 2015-07-30 US US15/500,351 patent/US10098884B2/en active Active
- 2015-07-30 EP EP23205570.7A patent/EP4311575A3/en not_active Withdrawn
- 2015-07-30 EP EP20191599.8A patent/EP3791883B1/en active Active
-
2017
- 2017-09-08 US US15/699,559 patent/US10272089B2/en active Active
-
2019
- 2019-04-29 US US16/397,562 patent/US10828306B2/en active Active
-
2020
- 2020-10-30 US US17/085,907 patent/US20210283135A1/en not_active Abandoned
- 2020-12-07 JP JP2020202357A patent/JP2021059554A/ja active Pending
-
2023
- 2023-07-13 JP JP2023114963A patent/JP2023145527A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523974A5 (https=) | ||
| Pérez-Torregrosa et al. | Combined phacoemulsification and XEN45 surgery from a temporal approach and 2 incisions | |
| Tyson et al. | Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery | |
| Donnenfeld et al. | Dexamethasone intracameral drug-delivery suspension for inflammation associated with cataract surgery: a randomized, placebo-controlled, phase III trial | |
| Voskanyan et al. | Prospective, unmasked evaluation of the iStent® inject system for open-angle glaucoma: synergy trial | |
| Hoeh et al. | Early postoperative safety and surgical outcomes after implantation of a suprachoroidal micro-stent for the treatment of open-angle glaucoma concomitant with cataract surgery | |
| JP2021059554A5 (https=) | ||
| Cao et al. | Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation | |
| Agrawal et al. | Cataract surgery in uveitis | |
| Walters et al. | Efficacy and safety of sustained release dexamethasone for the treatment of ocular pain and inflammation after cataract surgery: results from two phase 3 studies | |
| Bratton et al. | Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis | |
| Donnenfeld et al. | Safety of IBI-10090 for inflammation associated with cataract surgery: phase 3 multicenter study | |
| Fadlallah et al. | Safety and efficacy of femtosecond laser–assisted arcuate keratotomy to treat irregular astigmatism after penetrating keratoplasty | |
| Mylonas et al. | Macular edema following cataract surgery in eyes with previous 23-gauge vitrectomy and peeling of the internal limiting membrane | |
| Delyfer et al. | Adapted surgical procedure for Argus II retinal implantation: feasibility, safety, efficiency, and postoperative anatomic findings | |
| Larochelle et al. | Dexamethasone intravitreal implant in the treatment of uveitic macular edema in the perioperative cataract setting: a case series | |
| Tai et al. | Surgical outcomes of Baerveldt implants in pediatric glaucoma patients | |
| Bhargava et al. | Phacoemulsification versus manual small incision cataract surgery in patients with fuchs heterochromic iridocyclitis | |
| Yildirim et al. | Same-day intrastromal corneal ring segment and collagen cross-linking for ectasia after laser in situ keratomileusis: long-term results | |
| Crawford et al. | Endocapsular artificial iris implantation for iris defects: reducing symptoms, restoring visual function and improving cosmesis | |
| Nagpal et al. | Topical nepafenac 0.1% alone versus prednisolone acetate 1% as postoperative anti-inflammatory agents in small gauge vitrectomy | |
| Eshraghi et al. | Scleral buckle removal: indications, timing, complications, and long-term outcomes | |
| García et al. | Management of the neovascular choroidal membrane secondary to ocular toxoplasmosis | |
| Kilavuzoğlu et al. | Treatment of mixed astigmatism: early clinical outcomes with WaveLight and Technolas excimer lasers | |
| Abdelaziz et al. | Collagen corneal cross-linking followed by Intac implantation in a case of post-PRK ectasia |